AEON Biopharma (NYSE: AEON) investors back Class III board slate and KPMG

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

AEON Biopharma, Inc. reported results from its Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected Marc Forth and Seongsoo Park as Class III directors to terms ending at the 2029 annual meeting, with 13,297,322 and 13,117,299 votes "for," respectively.

Stockholders also ratified the appointment of KPMG LLP as AEON Biopharma’s independent registered public accounting firm for the fiscal year ended December 31, 2026, with 21,502,418 votes "for," 18,217 "against" and 1,498 "abstain."

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Marc Forth: 13,297,322 votes Votes for Seongsoo Park: 13,117,299 votes Broker non-votes on director elections: 8,197,073 votes +3 more

6 metrics

Votes for Marc Forth 13,297,322 votes Election as Class III director, term expiring 2029

Votes for Seongsoo Park 13,117,299 votes Election as Class III director, term expiring 2029

Broker non-votes on director elections 8,197,073 votes For each Class III director election

Votes for KPMG ratification 21,502,418 votes Ratification of KPMG LLP as auditor for fiscal year ended Dec. 31, 2026

Votes against KPMG ratification 18,217 votes Ratification of KPMG LLP for 2026 fiscal year

Abstentions on KPMG ratification 1,498 votes Ratification of KPMG LLP for 2026 fiscal year

Key Terms

Annual Meeting of Stockholders, Class III directors, broker non-vote, independent registered public accounting firm, +1 more

5 terms

Annual Meeting of Stockholders financial

"held its Annual Meeting of Stockholders on June 17, 2026"

Class III directors financial

"elected each of Marc Forth and Seongsoo Park as Class III directors"

Class III directors are members of a company’s board assigned to one of several staggered term groups, so only that class faces election in a particular year while other classes stay in place. For investors this affects corporate control and takeover risk because staggered elections make it slower and harder for an outside group to replace a majority of directors quickly—think of it as a rotating schedule for board seats that provides continuity but can also entrench existing leadership.

broker non-vote financial

"For, Withheld, Broker Non-Vote"

independent registered public accounting firm financial

"KPMG LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/17/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2026

AEON Biopharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40021

85-3940478

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

5 Park Plaza

Suite 1750

Irvine, CA 92614

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (949) 354-6499

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	AEON	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

AEON Biopharma, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 17, 2026 (the “Annual Meeting”) as described in the Company’s proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2026 (the “2026 Proxy”). At the Annual Meeting, the stockholders of the Company voted on two proposals as further described in the 2026 Proxy. The final results for each proposal voted on by the stockholders at the Annual Meeting, as certified by the Company’s inspector of elections, are set forth below.

Proposal 1: The stockholders of the Company elected each of Marc Forth and Seongsoo Park as Class III directors of the Company’s board of directors (the “Class III Directors”) for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029 and until their respective successors have been duly elected and qualified. The voting results with respect to the election of the Class III Directors were as follows:


Nominee	Term Expiring	For	Withheld	Broker Non-Vote
Marc Forth	2029	13,297,322	27,738	8,197,073
Seongsoo Park	2029	13,117,299	207,761	8,197,073

Proposal 2: The stockholders of the Company ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. The voting results for this proposal were as follows:


For	Against	Abstain	Broker Non-Vote
21,502,418	18,217	1,498	—

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	AEON Biopharma, Inc.
Date: June 17, 2026	By:	/s/ Robert Bancroft
		Robert Bancroft
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did AEON (AEON) shareholders vote on at the 2026 annual meeting?

Shareholders voted on two items: electing Marc Forth and Seongsoo Park as Class III directors and ratifying KPMG LLP as AEON Biopharma’s independent registered public accounting firm for the fiscal year ended December 31, 2026.

Were AEON (AEON) director nominees elected at the June 17, 2026 meeting?

Yes. Marc Forth and Seongsoo Park were elected as Class III directors. Their terms run until the annual meeting of stockholders to be held in 2029 and until their respective successors are duly elected and qualified.

How many votes did AEON director nominee Marc Forth receive?

Marc Forth received 13,297,322 votes "for" and 27,738 votes "withheld," with 8,197,073 broker non-votes. These results certified his election as a Class III director with a term expiring at the 2029 annual meeting.

How many votes did AEON director nominee Seongsoo Park receive?

Seongsoo Park received 13,117,299 votes "for" and 207,761 votes "withheld," along with 8,197,073 broker non-votes. This voting outcome confirmed his election as a Class III director through the 2029 annual meeting of stockholders.

Did AEON (AEON) stockholders ratify KPMG LLP as auditor for 2026?

Yes. Stockholders ratified KPMG LLP as AEON Biopharma’s independent registered public accounting firm for the fiscal year ended December 31, 2026, with 21,502,418 votes "for," 18,217 "against," 1,498 "abstain," and no broker non-votes reported.

What is a broker non-vote in AEON’s 2026 annual meeting results?

A broker non-vote appears where brokers did not have authority to vote uninstructed shares on a proposal. AEON reported 8,197,073 broker non-votes for each director election proposal, while no broker non-votes were recorded for the auditor ratification.

Filing Exhibits & Attachments

4 documents